COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,719 Articles (22,913 medRxiv, 8,806 bioRxiv)

Most recent first Previous |  Page 748: Articles 7471-7480  | Next

Pangenome analysis of SARS-CoV2 strains to Identify Potential vaccine targets by Reverse Vaccinology
Tariq, M. H., Amir, A., Irshad, H.
10.1101/2022.07.15.500170 — Posted: 2022-07-15
Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
Ragonnet-Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., Hartman, H., Ellaby, N., Sutton, J. M., Bahar, M. W., Zhou, D., Fry, E., Ren, J., Brown, C., Klenerman, P., Dunachie, S. J., Mongkolsapaya, J., Hopkins, S., Chand, M., Stuart, D. I., Screaton, G. R., Rokadiya, S.
10.1101/2022.07.14.500063 — Posted: 2022-07-15
Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies
Yamasoba, D., Kimura, I., Kosugi, Y., Uriu, K., Fujita, S., Ito, J., Sato, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium
10.1101/2022.07.14.500041 — Posted: 2022-07-15
Vitamin C is an efficient natural product for prevention of SARS-CoV-2 infection by targeting ACE2 in both cell and in vivo mouse models
Zuo, Y., Zheng, Z., Huang, Y., He, J., Zang, L., Ren, T., Cao, X., Miao, Y., Yuan, Y., Liu, Y., Ma, F., Tian, S., Dai, J., Ding, Q., Zheng, H.
10.1101/2022.07.14.499651 — Posted: 2022-07-15
A zebrafish model of COVID-19-associated cytokine storm syndrome reveals that the Spike protein signals via TLR2
Tyrkalska, S. D., Martinez-Lopez, A., Pedoto, A., Candel, S., Cayuela, M. L., Mulero, V.
10.1101/2022.07.14.500031 — Posted: 2022-07-15
Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine
Leekha, A., Saeedi, A., Sefat, S. R., Kumar, M., Paniagua, M. M., Damian, A., Kulkarni, R., Rezvan, A., Mosoumi, S., Liu, X., Cooper, L. J. N., Sebastian, M., Hurst, B. L., Varadarajan, N.
10.1101/2022.07.14.500068 — Posted: 2022-07-15
SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1
Richardson, S., Motlou, T., van der Mescht, M., Lambson, B., Everatt, J., Amoako, D., Van Gottberg, A., Wolter, N., de Beer, Z., Roma de Villiers, T., Bodenstein, A., van den Berg, G., Rossouw, T. M., Boswell, M., Ueckermann, V., Bhiman, J., Moore, P.
10.1101/2022.07.14.500039 — Posted: 2022-07-15
Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant
Richardson, S., Kgagudi, P., Manamela, N. P., Kaldine, H., Venter, E., Pillay, T., Lambson, B. E., van der Mescht, M., Hermanus, T., de Beer, Z., de Villier, T., Bodenstein, A., van den Berg, G., du Pisanie, M., Burgers, W., Ntusi, N. A. B., Ueckermann, V., Rossouw, T., Boswell, M., Moore, P.
10.1101/2022.07.14.500042 — Posted: 2022-07-15
Practical application of CO2 as an indicator regarding the risk of infection
Hartmann, A., Cetin, Y. E., Gastmeier, P., Kriegel, M.
10.1101/2022.07.14.22277631 — Posted: 2022-07-15
Sudden hearing loss following vaccination against COVID-19
Nieminen, T., Kivekas, I., Artama, M., Nohynek, H., Kujansivu, J., Hovi, P.
10.1101/2022.07.10.22277380 — Posted: 2022-07-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).